Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Common Equity (2016 - 2021)

ENDRA Life Sciences (NDRA) has disclosed Common Equity for 6 consecutive years, with $13.2 million as the latest value for Q3 2021.

  • Quarterly Common Equity rose 294.49% to $13.2 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $13.2 million through Sep 2021, up 294.49% year-over-year, with the annual reading at $7.2 million for FY2020, 50.59% up from the prior year.
  • Common Equity for Q3 2021 was $13.2 million at ENDRA Life Sciences, down from $15.0 million in the prior quarter.
  • The five-year high for Common Equity was $17.9 million in Q1 2021, with the low at -$1.4 million in Q1 2017.
  • Average Common Equity over 5 years is $5.3 million, with a median of $3.8 million recorded in 2019.
  • The sharpest move saw Common Equity tumbled 106.38% in 2018, then soared 1434.47% in 2021.
  • Over 5 years, Common Equity stood at $5.3 million in 2017, then grew by 18.44% to $6.2 million in 2018, then dropped by 23.81% to $4.8 million in 2019, then skyrocketed by 50.59% to $7.2 million in 2020, then surged by 83.51% to $13.2 million in 2021.
  • According to Business Quant data, Common Equity over the past three periods came in at $13.2 million, $15.0 million, and $17.9 million for Q3 2021, Q2 2021, and Q1 2021 respectively.